Engineered antibody Fc variants with enhanced effector function

被引:605
作者
Lazar, GA [1 ]
Dang, W [1 ]
Karki, S [1 ]
Vafa, O [1 ]
Peng, JS [1 ]
Hyun, L [1 ]
Chan, C [1 ]
Chung, HS [1 ]
Eivazi, A [1 ]
Yoder, SC [1 ]
Vielmetter, J [1 ]
Carmichael, DF [1 ]
Hayes, RJ [1 ]
Dahiyat, BI [1 ]
机构
[1] Xencor Inc, Monrovia, CA 91016 USA
关键词
antibody-dependent cell-mediated cytotoxicity; Fc gamma R; protein engineering; cancer;
D O I
10.1073/pnas.0508123103
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Antibody-dependent cell-mediated cytotoxicity, a key effector function for the clinical efficacy of monoclonal antibodies, is mediated primarily through a set of closely related Fc gamma receptors with both activating and inhibitory activities. By using computational design algorithms and high-throughput screening, we have engineered a series of Fc variants with optimized Fc gamma receptor affinity and specificity. The designed variants display > 2 orders of magnitude enhancement of in vitro effector function, enable efficacy against cells expressing low levels of target antigen, and result in increased cytotoxicity in an in vivo preclinical model. Our engineered Fc regions offer a means for improving the next generation of therapeutic antibodies and have the potential to broaden the diversity of antigens that can be targeted for antibody-based tumor therapy.
引用
收藏
页码:4005 / 4010
页数:6
相关论文
共 41 条
[31]   MAPPING AND COMPARISON OF THE INTERACTION SITES ON THE FC REGION OF IGG RESPONSIBLE FOR TRIGGERING ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) THROUGH DIFFERENT TYPES OF HUMAN FC-GAMMA RECEPTOR [J].
SARMAY, G ;
LUND, J ;
ROZSNYAY, Z ;
GERGELY, J ;
JEFFERIS, R .
MOLECULAR IMMUNOLOGY, 1992, 29 (05) :633-639
[32]   Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity [J].
Shields, RL ;
Lai, J ;
Keck, R ;
O'Connell, LY ;
Hong, K ;
Meng, YG ;
Weikert, SHA ;
Presta, LG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (30) :26733-26740
[33]   High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR [J].
Shields, RL ;
Namenuk, AK ;
Hong, K ;
Meng, YG ;
Rae, J ;
Briggs, J ;
Xie, D ;
Lai, J ;
Stadlen, A ;
Li, B ;
Fox, JA ;
Presta, LG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (09) :6591-6604
[34]   Molecular basis for immune complex recognition: A comparison of Fc-receptor structures [J].
Sondermann, P ;
Kaiser, J ;
Jacob, U .
JOURNAL OF MOLECULAR BIOLOGY, 2001, 309 (03) :737-749
[35]   Lysine 322 in the human IgG3 CH2 domain is crucial for antibody dependent complement activation [J].
Thommesen, JE ;
Michaelsen, TE ;
Loset, GÅ ;
Sandlie, I ;
Brekke, OH .
MOLECULAR IMMUNOLOGY, 2000, 37 (16) :995-1004
[36]   The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy [J].
Uchida, JJ ;
Hamaguchi, Y ;
Oliver, JA ;
Ravetch, JV ;
Poe, JC ;
Haas, KM ;
Tedder, TF .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (12) :1659-1669
[37]  
Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719
[38]   Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG [J].
Vugmeyster, YL ;
Howell, K .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2004, 4 (08) :1117-1124
[39]  
Warren HS, 1999, J IMMUNOL, V162, P735
[40]   Tunable antibodies [J].
Weiner, LM ;
Carter, P .
NATURE BIOTECHNOLOGY, 2005, 23 (05) :556-557